Everolimus combination improved progression-free survival in neuroendocrine tumors Oncology Nurse Advisor Progression-free survival improved in patients with advanced neuroendocrine tumors associated with carcinoid syndrome when the patients used everolimus rather than placebo in combination with octreotide long-acting repeatable (LAR). ... |
